SAT0235 BIIB059, a monoclonal antibody targeting BCDA2 shows safety, tolerability, pharmacokinetics, pharmacodynamics in healthy volunteer subjects - Martin, D; Stevenson, L; Prasad, P; Smirnakis, K; Kao, A; Rabah, D; Wang, W; Barbey, C; Musselli, C; Franchimont, N (Annals of the rheumatic diseases, 2017)
Keywords: Bioavailability; Cell surface; Dendritic cells; Drug dosages; EKG; Enzyme-linked immunosorbent assay; Flow cytometry; Inflammation; Interferon; Internalization; Monoclonal antibodies; Pharmacodynamics; Pharmacokinetics; Safety; Stockholders; Systemic lupus erythematosus